top of page

USPSTF Rules Out Aspirin for Over 60s in Primary CVD Prevention

New draft recommendations from the US Preventive Services Task Force (USPSTF) on the use of aspirin for the primary prevention of cardiovascular disease (CVD) have been released and appear to limit the population in which it should be considered.

"The USPSTF concludes with moderate certainty that aspirin use for the primary prevention of CVD events in adults ages 40 to 59 years who have a 10% or greater 10-year CVD risk has a small net benefit," the recommendation notes. They conclude that for these patients, the decision to use aspirin "should be an individual one."

"Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit," they note.

For older individuals, however, "The USPSTF concludes with moderate certainty that initiating aspirin use for the primary prevention of CVD events in adults age 60 years or older has no net benefit," the task force concludes.


2 views0 comments

Recent Posts

See All

Comments


bottom of page